Clinical Trials

At Imugene, we are dedicated to advancing healthcare through innovative clinical trials. Our research focuses on developing new treatments for a range of blood cancers.

Consistent with our commitment to bring innovative, safe, and effective therapies to patients, we are focused on conducting the clinical trials necessary to gain regulatory approvals to make our therapies broadly available to patients. Participation in our clinical trials is the best way to access our investigational therapies.

“Expanded Access” is a pathway to use unapproved treatments outside of clinical trials, usually for severe or life-threatening conditions. At this time, Imugene does not have an expanded access program for any of our products and participation in our clinical study is the only way to access our investigational products.

Our lead candidate, azer-cel is currently in an active Phase 1b clinical trial in Australia and the United States and we encourage patients and physicians interested in learning more about our ongoing studies, participating locations and eligibility criteria by visiting clinicaltrials.gov and searching for Imugene Limited.

Participation in Imugene clinical trials is always based on the patient’s own decision. As the sponsor of our clinical trials, Imugene cannot be directly involved in the recruitment process. For further information on how to participate in a clinical trial, please contact your treating physician.